Inspired by the therapeutic potential of cannabis and its derivatives, Adam Rosenberg has dedicated his career to shaping the industry as an operator, investor, advisor, and educator across state-regulated cannabis, biopharmaceuticals, and hemp. He currently serves as the Chairman of the Board of the National Cannabis Industry Association. In biopharmaceuticals, Adam advises executives and manages investment funds for companies pursuing FDA approval for cannabis-derived therapeutics including AJNA BioSciences, DeFloria, Andira Pharmaceuticals, and Pure Green Pharmaceuticals.